Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications

Author:

Godman Brian,Petzold Max,Bennett Kathleen,Bennie Marion,Bucsics Anna,Finlayson Alexander E,Martin Andrew,Persson Marie,Piessnegger Jutta,Raschi Emanuel,Simoens Steven,Zara Corinne,Barbui Corrado

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Reference88 articles.

1. Godman B, Campbell S, Suh HS, Finlayson AE, Bennie M, Gustafsson LL: Ongoing measures to enhance prescribing efficiency across Europe: implications for other countries. J Health Tech Assess. 2013, 1: 27-42.

2. Malmström RE, Godman B, Diogene E, Baumgärtel C, Bennie M, Bishop I, Brzezinska A, Bucsics A, Campbell S, Ferrario A, Finlayson AE, Fürst J, Garuoliene K, Gomes M, Gutiérrez-Ibarluzea I, Haycox A, Hviding K, Herholz H, Hoffmann M, Jan S, Jones J, Joppi R, Kalaba M, Kvalheim C, Laius O, Langner I, Lonsdale J, Lööv SÄ, Malinowska K, McCullagh L, et al: Dabigatran - a case history demonstrating the need for comprehensive approaches to optimise the use of new drugs. Front Pharmacol. 2013, 4: 1-19. doi:10.3389/fphar.2013.00039

3. Godman B, Finlayson AE, Cheema PK, Zebedin-Brandl E, Gutiérrez-Ibarluzea I, Jones J, Malmström RE, Asola E, Baumgärtel C, Bennie M, Bishop I, Bucsics A, Campbell S, Diogene E, Ferrario A, Fürst J, Garuoliene K, Gomes M, Harris K, Haycox A, Herholz H, Hviding K, Jan S, Kalaba M, Kvalheim C, Laius O, Lööv SA, Malinowska K, Martin A, McCullagh L, et al: Personalising health care: feasibility and future implications. BMC Med. 2013, 11: 179.

4. Garuoliene K, Godman B, Gulbinovič J, Wettermark B, Haycox A: European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev Pharmacoeconomics Outcomes Res. 2011, 11: 343-349.

5. Taylor L: Australian government blocks subsidies for new drugs. 2011, Available via URL: http://www.pharmatimes.com/Article/11-03-15/Australian_govt_blocks_subsidies_for_new_drugs.aspx [Accessed January 2013]

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3